1. DrugWatch . FDA recalls, https://www.drugwatch.com/fda/recalls/ (accessed 6 December 2020).
Google Scholar2. Byrd, JB, Chertow, GM, Bhalla, V. Hypertension hot potato - anatomy of the angiotensin-receptor blocker recalls. N Engl J Med 2019; 380: 1589–1591.
Google Scholar | Crossref | Medline3. Food & Drug Administration . FDA statement on the agency’s list of known nitrosamine-free valsartan and ARB class medicines, as part of agency’s ongoing efforts to resolve ongoing safety issue, http://www.fda.gov/news-events/press-announcements/fda-statement-agencys-list-known-nitrosamine-free-valsartan-and-arb-class-medicines-part-agencys (accessed 6 December 2020).
Google Scholar4. Charoo, NA, Ali, AA, Buha, SK, et al. Lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities. AAPS PharmSciTech 2019; 20: 166.
Google Scholar | Crossref | Medline5. Whelton, PK, Carey, RM, Aronow, WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2018; 138: e426–e483.
Google Scholar | Medline6. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137–e161.
Google Scholar | Crossref | Medline7. Pfeffer, MA, McMurray, JJ, Velazquez, EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906.
Google Scholar | Crossref | Medline | ISI8. Switaj, TL, Christensen, SR, Brewer, DM. Acute coronary syndrome: current treatment. Am Fam Physician 2017; 95: 232–240.
Google Scholar | Medline9. Chapter 3: Management of progression and complications of CKD . Kidney Int Suppl (2011) 2013; 3: 73–90.
Google Scholar | Crossref | Medline10. American Diabetes Association. 10 . Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care 2020; 43(Suppl. 1): S111–S134.
Google Scholar | Crossref | Medline11. Sparks, MA, Crowley, SD, Gurley, SB, et al. Classical renin-angiotensin system in kidney physiology. Compr Physiol 2014; 4: 1201–1228.
Google Scholar | Crossref | Medline12. Barreras, A, Gurk-Turner, C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 2003; 16: 123–126.
Google Scholar | Crossref | Medline13. Eibner, C, Krull, H, Brown, KM, et al. Current and projected characteristics and unique health care needs of the patient population served by the Department of Veterans Affairs. Rand Health Q 2016; 5: 13.
Google Scholar | Medline14. U.S. Department of Veterans Affairs . Pharmacy benefits management services, http://www.pbm.va.gov/nationalformulary.asp (accessed 6 December 2020).
Google Scholar15. Veterans Health Administration Pharmacy Benefits Management Services . Valsartan-containing tablets, USP: recall due to detection of impurity. Washington, DC: VA MedSAFE, 2019.
Google Scholar16. Zhou, D, Xi, B, Zhao, M, et al. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III linked mortality study. Sci Rep 2018; 8: 9418.
Google Scholar | Crossref | Medline17. Jackevicius, CA, Krumholz, HM, Chong, A, et al. Population impact of generic valsartan recall. Circulation 2020; 141: 411–413.
Google Scholar | Crossref | Medline18. Thomas, K. Drug shortages persist in U.S., harming care. New York Times, 16 November 2012, https://www.nytimes.com/2012/11/17/business/drug-shortages-are-becoming-persistent-in-us.html?pagewanted=all&_r=0 (accessed 2 February 2021).
Google Scholar19. Food and Drug Administration . Questions and Answers: NDMA impurities in metformin products, https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-metformin-products (accessed 6 December 2020).
Google Scholar20. Food and Drug Administration . Zantac (ranitidine): safety information - NDMA found in samples of some ranitidine medicines, https://www.fda.gov/safety/medical-product-safety-information/zantac-ranitidine-safety-information-ndma-found-samples-some-ranitidine-medicines (accessed 6 December 2020).
Google Scholar21. McAlister, FA, Youngson, E. Impact of the generic valsartan recall in Alberta, Canada. J Am Coll Cardiol 2020; 75: 1860–1862.
Google Scholar | Crossref | Medline22. Desai, RJ, Sarpatwari, A, Gautam, N, et al. Changes in utilization of generic angiotensin receptor blockers following product recalls in the United States. JAMA 2020; 323: 87–89.
Google Scholar | Crossref | Medline23. Rudolph, UM, Enners, S, Kieble, M, et al. Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. J Hum Hypertens. Epub ahead of print 14 October 2020. DOI: 10.1038/s41371-020-00425-z.
Google Scholar | Crossref | Medline24. Pharmacist’s Letter . Angiotensin Receptor Blocker (ARB) antihypertensive dose comparison. https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2009/Aug/Angiotensin-Receptor-Blocker-ARB-Antihypertensive-Dose-Comparison-1718/ (accessed 6 December 2020).
Google Scholar